No Data
Wedbush Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $58
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data With Rusfertide at the 66th Annual ASH Meeting
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Protagonist Therapeutics Price Target Announced at $58.00/Share by Wedbush
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases
No Data
No Data